Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab Without Stem Cell Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

NCT04561206 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04561206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04561206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab Without Stem Cell Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
November 12, 2021
Completion date
October 2, 2027
Enrollment
31 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed classic hodgkin lymphoma